OGT Introduces New Array CGH Interpretation Software
CytoSure™ Interpret offers complete data integration and rapid analysis workflows for more
meaningful results
IMAGE: OGT CytoSure Interpret software - Automated aberration detection with CytoSure analysis software, showing clear detection of chromosomal abnormalities
For a high resolution image please contact neilr@alto-marketing.com
Oxford, UK – 10th December 2009. Oxford Gene Technology (OGT), the pioneer of
microarray-based technologies, has introduced its new CytoSure™ Interpret software, for
faster and easier translation of oligo aCGH data into meaningful results. This new release
builds on OGT’s previous software package with the addition of significant functionality such
as the ‘Accelerate’ workflow, for speeding-up and streamlining the analysis and
interpretation of aCGH data. Developed through consultation with users, CytoSure Interpret
ensures that cytogeneticists and molecular biologists benefit from highly flexible workflows
and in-depth contextual information for clearer data interpretation.
Dr. Agne Liedén from the Department of Molecular Medicine and Surgery, Karolinska
Institutet commented: “I am extremely impressed with the ease-of-use and flexibility of the
new CytoSure Interpret software. The main highlight for me is that I can include data
from our own results, multiple annotation tracks for known CNVs from all major sources, as
well as the population analysis tool.”
The CytoSure Interpret ‘Accelerate’ function enables the automation of data analysis
workflows, minimising the need for user intervention and maximising the consistency and
speed of data interpretation. Users are able to tailor the software to their needs, customising
numerous functions including normalisation, aberration detection and report generation.
Importantly, CytoSure Interpret provides comprehensive contextual input by fully integrating
results with legacy data, confirmation probe information (including FISH and MLPA), as well
as extensive annotation tracks covering syndromes, genes, exons, CNVs and recombination
hotspots. Furthermore, these link to publicly available databases such as Decipher and the
Database of Genomic Variants to provide even greater context.
James Clough, Commercial Director at OGT, stated: “The advanced functionality of
CytoSure Interpret is a result of our ongoing and extremely valuable discussions with our
users. We believe that CytoSure Interpret offers a step-change in the analysis and
interpretation of aCGH data, enabling researchers to handle large volumes of data to move
our understanding forward.”
In addition to this advanced interpretation software, the OGT CytoSure aCGH product line
includes a range of high quality arrays covering single disorders through to entire syndrome
spreads, as well as SciGene automation instrumentation (now distributed in Europe by
OGT). As a result, OGT’s comprehensive products and services are the ideal solution for
running oligo aCGH in the laboratory.
For further information on OGT products and services please visit http://www.ogt.co.uk.
Notes for editors:
About Oxford Gene Technology:
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.